Esketamine for treating major depressive disorder in adults at imminent risk of suicide (terminated appraisal) (TA899)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 6 June 2023
Esketamine nasal spray for treatment-resistant depression (TA854)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 14 December 2022
Vortioxetine for treating major depressive episodes (TA367)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 25 November 2015
Agomelatine for the treatment of major depressive episodes (terminated appraisal) (TA231)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 27 July 2011
Zuranolone for treating severe postnatal depression ID6431Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC